Table 67Quality-adjusted life-years and life years gained or lost over a 1-year period in the two base cases for 1,000 patients

Base CaseQALYs ESAQALYs TransfuseDifference (+ESA Better −ESA Worse)Life Years ESALife Years ControlDifference (+ESA Better −ESA Worse)
Curative intent660.2652.2+7.9961.6965.2−3.6
Non curative intent557.9554.0+3.9814.6823.8−9.2

ESA = erythropoiesis-stimulating agent; QALYs = quality-adjusted life years

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.